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TANK-binding kinase 1 (TBK1) is of central importance for
the induction of type-I interferon (IFN) in response to
pathogens. We identiﬁed the DEAD-box helicase DDX3X
as an interaction partner of TBK1. TBK1 and DDX3X acted
synergistically in their ability to stimulate the IFN promo-
ter, whereas RNAi-mediated reduction of DDX3X expres-
sion led to an impairment of IFN production. Chromatin
immunoprecipitation indicated that DDX3X is recruited to
the IFN promoter upon infection with Listeria monocyto-
genes, suggesting a transcriptional mechanism of action.
DDX3X was found to be a TBK1 substrate in vitro and
in vivo. Phosphorylation-deﬁcient mutants of DDX3X failed
to synergize with TBK1 in their ability to stimulate the IFN
promoter. Overall, our data imply that DDX3X is a critical
effector of TBK1 that is necessary for type I IFN induction.
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Introduction
Innate immune responses are stimulated when microbial
molecules referred to as pathogen-associated molecular pat-
terns (PAMPs) bind to a cognate pattern recognition receptor
(PRR) (Medzhitov and Janeway, 1997). PRRs can be ex-
pressed at the cell surface, the endosomal compartment or
in the cytoplasm of mammalian cells (Akira, 2006). Three
major families of PRRs have been identiﬁed: the Toll-like
receptors (TLRs), the RIG-I-like RNA helicases and the NOD-
like receptors (NLRs). A total of 11 different TLRs interact
with lipid, protein or nucleic acid PAMPs either at the cell
surface or the endosome (Akira, 2006). By contrast, the RIG-I-
like helicases exclusively detect cytosolic RNA of viral origin
(Yoneyama and Fujita, 2007). The NLRs bind to a large
variety of PAMPs or danger-associated molecular patterns
that include peptides, small molecules and nucleic acids
(Kanneganti et al, 2007; Petrilli et al, 2007). Cytosolic DNA,
a PAMP resulting from infection with DNA-containing intra-
cellular pathogens, is recognized by a yet unknown number
of DNA receptors. One component of the DNA recognition
machinery is DAI (DLM-1/ZBP1), a protein that does not
belong to either of the three major PRR families (Ishii et al,
2006, 2008; Takaoka et al, 2007; Wang et al, 2008).
PRR engagement triggers several intracellular signalling
cascades that culminate in the production and secretion of
pro-inﬂammatory cytokines, chemokines and type-I interfer-
ons (IFNs) (predominantly IFN-a and -b collectively termed
IFN-I (Pestka et al, 2004; Kawai and Akira, 2007a,b)). These
secreted mediators, in turn, activate a gene expression pro-
gramme and orchestrate a protective immune response
against the invading pathogen.
Interferons are the most important antiviral cytokines and
loss of IFN-I signalling leads to a severe immunodeﬁciency
towards viral infection (Muller et al, 1994). As a primary
response to infection, IFN-b production can be triggered by
several PRRs, most notably TLR3 and TLR4, RIG-I and MDA5
and the cytoplasmic DNA receptors. TLR-induced signalling
is initiated by the recruitment of an adaptor called TRIF and
proceeds through the ubiquitin ligase TRAF3 and the kinases
TANK-binding kinase 1 (TBK1)/IKK-i to phosphorylate and
activate the transcription factors IFN-regulatory factors (IRF)
3 and 7 (Akira, 2006; Honda and Taniguchi, 2006; He et al,
2007). RIG-I and MDA5 signalling uses a different adaptor
called MAVS (IPS-1, VISA, Cardif; Kawai et al, 2005; Meylan
et al, 2005; Xu et al, 2005; Sun et al, 2006), but also involves
TRAF3, TBK1/IKK-i and IRF3/IRF7 (Saha et al, 2006;
Yoneyama and Fujita, 2007). DNA-mediated signalling in-
itiated by DAI (DLM-1/ZBP1) and/or additional cytoplasmic
receptors is poorly understood, but similar to the other PRRs
it funnels into the TBK1/IKK-i–IRF3 pathway to activate the
IFN-b gene (Ishii et al, 2006; Takaoka et al, 2007).
A plethora of studies thus converge to emphasize the role
of TBK1 as an activator of IRF3, hence as a central regulator
of IFN-I genes in response to many different PAMPs. TBK1-
mediated phosphorylation of IRF3 is believed to occur in the
C-terminal domain of IRF3 and triggers a conformational
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2135change that allows for the dimerization and subsequent
nuclear translocation of IRF3 (Honda and Taniguchi, 2006;
Hiscott, 2007). In some cells, TBK1 function is shared by the
highly related IKK-i (or IKKe) kinase, whereas in others TBK1
has a non-redundant function as an IRF3 kinase (Hemmi
et al, 2004; McWhirter et al, 2004; Matsui et al, 2006).
The Gram-positive bacterium Listeria monocytogenes has
adapted to an intracellular lifestyle by virtue of its ability to
escape from endosomal or phagosomal compartments to the
cytoplasm of the host cell (Portnoy et al, 2002; Hamon et al,
2006). Disruption of the endosomal/phagosomal membrane
results from the activity of the major Listeria virulence
protein, a haemolysin called Listeriolysin O (Schnupf and
Portnoy, 2007). Intracellular infection with L. monocytogenes
stimulates robust expression of IFN-I genes and this was
shown to require TBK1 as well as IRF3 (O’Connell et al,
2004, 2005; Stockinger et al, 2004; Decker et al, 2005). The
nature of the PAMP delivered to the cytoplasm by L. mono-
cytogenes, although speculatively DNA (Stetson and
Medzhitov, 2006), requires ﬁnal clariﬁcation. None of the
known PRR adapters are essential to connect the Listeria
ligand and TBK1 (Stockinger et al, 2004; Soulat et al, 2006;
Sun et al, 2006). The L. monocytogenes ligand and cytoplas-
mic DNA pathways thus share the lack of known players to
address and activate TBK1.
To start bridging the gap between the L. monocytogenes
ligand and the IRF3 pathway, we sought to identify TBK1-
interacting proteins from macrophages. We report here the
surprising ﬁnding that a DEAD-box helicase not closely
related to, and with properties clearly distinct from, the
RIG-I family is phosphorylated by TBK1 to enhance expres-
sion of IFN-I genes.
Results
Identiﬁcation of DDX3X as a novel TBK1 target
To identify novel interactors of TBK1, we generated stable
RAW264.7 cell lines that express a GS-TAP-tagged version of
TBK1 and puriﬁed the TBK1 protein complex by tandem
afﬁnity puriﬁcation (Figure 1A and B) (Burckstummer et al,
2006). Mass spectrometry analysis identiﬁed TBK1 along
with the core complex components TRAF family member-
associated NF-kappa-B activator (TANK; 17 peptides), TBK-
binding protein 1 (TBKBP1, also referred to as SINTBAD; 10
peptides) and TBKBP2 (also referred to as NAP1 or AZI2; 15
peptides), indicating that this native puriﬁcation was efﬁcient
and in agreement with previously published data on the
TBK1 core complex (Bouwmeester et al, 2004). In addition,
we identiﬁed the DEAD-box helicase DDX3X (RefSeq
NP_034158) with ﬁve peptides. Immunoprecipitation experi-
ments using tagged TBK1 suggested that its interaction with
DDX3X and the transcription factor IRF3 are signiﬁcantly
weaker than the interaction between TBK1 and TANK and
therefore not detected by coimmunoprecipitation under strin-
gent conditions (Supplementary Figure 1A). Likewise, we
could not detect any association of DDX3X with IRF3
(Supplementary Figure 1B).
Requirement of DDX3X for IFN-b production
We addressed the functional relevance of the TBK1/DDX3X
interaction by reducing DDX3X expression and measuring the
impact on type-I IFN production. siRNA transfection led to a
decrease in DDX3X or TBK1 expression by at least
50% (Figure 2A and B). The cells were infected with
L. monocytogenes and IFN-b mRNA production was evalu-
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Figure 1 The DEAD-box helicase DDX3X is a target of TBK1. (A) Schematic representation of the tandem afﬁnity puriﬁcation protocol:
GS-TAP-tagged TBK1 expressed in RAW264.7 cells was puriﬁed using rabbit immunoglobulin G (IgG) agarose and eluted by tobacco etch
virus (TEV) protease cleavage. Next, the remaining complex was puriﬁed using streptavidin agarose and eluted by boiling in SDS sample buffer.
(B) The ﬁnal TAP eluate was separated on an SDS–PAGE and stained by silver staining. Protein complex composition was analysed by
LC-MSMS. The position of several complex components is depicted next to the region where it was identiﬁed.
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Figure 2 DDX3X is required for IFN-b induction. Expression of TBK1 or DDX3X was targeted in RAW264.7 macrophages using speciﬁc siRNAs.
Expression levels of TBK1 (A) or DDX3X (B) were monitored by immunoblotting. Pan-ERK was monitored as a loading control. (C) siRNA-
treated RAW264.7 cells were infected with L. monocytogenes for 4h. Induction of IFN-b mRNA (left panel), RANTES mRNA (middle panel) and
TNF-a mRNA (right panel) were measured by quantitative RT–PCR. (D) Similar cells were transfected with poly(I:C) (left panel), treated with
LPS (middle panel) or transfected with poly(dA:dT) (right panel). Induction of IFN-b mRNAwas measured by quantitative RT–PCR. (E) siRNA-
treated RAW264.7 cells were infected with L. monocytogenes or treated with IFN-b for 4h. Induction of IRF7 and Mx2 was measured by
quantitative RT–PCR. Sets of data were analysed using the paired Student’s t-test (two-tailed, equal variance). Statistical signiﬁcance was
assessed based on the P-value: *Po0.05, **Po0.01 and ***Po0.001.
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quired for IFN-b mRNA transcription (Figure 2C). Strikingly,
we observed the same level of reduction for the cells in which
DDX3X expression was reduced by siRNA, suggesting that
DDX3X is necessary for IFN-b induction. Similar results were
obtained for Listeria-mediated induction of RANTES
(Figure 2C), another IRF3-dependent gene. To verify that
the DDX3X knockdown does not have a general effect on
the response to L. monocytogenes, we measured the induction
of TNF-a after infection. TNF-a is strongly induced upon
L. monocytogenes infection (data not shown), but it does not
rely on the TBK1/IRF3 axis (Doyle et al, 2002). In agreement
with this, we did not observe any defect in the TNF-a
induction neither when TBK1 nor when DDX3X expression
was reduced by RNA interference (Figure 2C).
Next, we wanted to address whether DDX3X has a speciﬁc
role during L. monocytogenes infection or a more general role
in IFN-b induction. To this end, we stimulated the siRNA-
treated cells with different PAMPs such as LPS, transfected
poly(I:C) or transfected poly(dA:dT) targeting, respectively,
TLR4, MDA5 or the cytosolic DNA receptor. In all of these
experimental conditions, reduction of DDX3X expression
caused a decrease in IFN-b induction (Figure 2D), conﬁrming
that DDX3X is necessary for type-I IFN induction in general.
TBK1/IRF3-mediated production of IFN-b triggers a posi-
tive feedback loop to fortify IFN production (Honda et al,
2005). Newly produced IFN-b engages the type-I IFN receptor
(IFNAR) which, in turn, stimulates the production of IRF7.
Subsequently, IRF7 cooperates with IRF3 to cause a second
wave of type-I IFN production. To address whether DDX3X is
also involved in this second loop of signalling initiated by
IFNAR engagement, we decided to analyse the impact of
reduced DDX3X expression on IRF7 transcription. We ob-
served a diminished IRF7 induction upon TBK1 or DDX3X
knockdown in cells infected with L. monocytogenes
(Figure 2E) and this reduction was similar to the one ob-
served for induced expression of the IFN-b gene (Figure 2C).
By contrast, there was no effect of the TBK1 or DDX3X
knockdown on the IFN-b-stimulated IRF7 expression
(Figure 2E). Similar results were obtained for Mx2, another
downstream target of the IFNAR (Figure 2E), indicating that
DDX3X does not have a function in IFN-induced gene ex-
pression. Overall, these experiments suggest that DDX3X is
required for TBK1/IRF3-mediated IFN-b production.
Impact of TBK1 on DDX3X function
The function of DDX3X that may be best documented so far is
its role in the nuclear export of human immunodeﬁciency
virus-1 (HIV-1) mRNA. To test whether this function is
affected by TBK1 activity, we used an established experi-
mental set-up involving a Rev reporter plasmid (Yedavalli
et al, 2004). This assay monitors the DDX3X-dependent
nuclear export of a Rev response element-containing RNA
encoding the CAT gene (Figure 3A). We found that DDX3X by
itself has only a moderate impact on Rev-mediated nuclear
export (Figure 3B). Coexpression of TBK1 strongly increased
the activity of DDX3X. This effect was neither seen with an
inactive mutant of TBK1 (K38M) (Fitzgerald et al, 2003) nor
with an ATPase-deﬁcient mutant of DDX3X (K230A)
(Yedavalli et al, 2004), implying that both the kinase activity
of TBK1 and the helicase activity of DDX3X are required for
this function of DDX3X.
Synergistic activation of the IFN-b promoter by TBK1
and DDX3X
Is DDX3X sufﬁcient to activate the IFN promoter? We decided
to address this question using an IFN-b reporter plasmid in
HEK293 cells. MAVS and, to a lesser extent, TBK1 induced the
IFN-b promoter, whereas DDX3X by itself did not (Figure 4A).
Nevertheless, coexpression of TBK1 with DDX3X led to a
synergistic promoter activation that was also observed for the
ATPase-deﬁcient mutant of DDX3X (Figure 4A), indicating
that the ATPase and the helicase functions of DDX3X are
dispensable for its synergy with TBK1. DDX3X did not
synergize with TBK1 with regard to NF-kB promoter induc-
tion (Figure 4B), sustaining the speciﬁc role of DDX3X in the
IFN pathway.
Next, we performed epistasis analyses to position DDX3X
in the IRF3 pathway. To this end, we used mouse embryonic
ﬁbroblasts (MEFs) from TBK1- or IRF3-deﬁcient mice along
with wild-type controls. Again, MAVS was a strong activator
of IFN-b and MAVS-mediated activation depended more on
the presence of IRF3 than on TBK1 (Figure 4C). This result
can be attributed to a certain degree of redundancy between
TBK1 and IKK-i (Hemmi et al, 2004). When TBK1 was
expressed at low levels (compare Supplementary Figure 2),
TBK1 by itself was only a weak inducer of IFN-b. In contrast,
DDX3X and TBK1 together gave a strong synergistic
activation of the IFN-b promoter (Figure 4C). Importantly,
this effect was also seen in TBK1 /  MEFs, but not in
IRF3 /  MEFs, conﬁrming that the DDX3X effect on IFN
requires TBK1 and does not bypass the requirement for IRF3.
Noteworthy, this synergy depends on kinase activity of TBK1
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Figure 3 TBK1 has an impact on Rev/DDX3X-dependent nuclear
RNA export. (A) Schematic representation of the Rev reporter
construct pDM128. In the absence of Rev-mediated nuclear mRNA
export, the CAT gene is spliced and therefore not translated. If Rev is
present, the mRNA is exported out of the nucleus, splicing is
prevented and the CAT mRNA is translated. (B) HEK293 cells
were transfected with the reporter plasmid pDM128 and constant
amounts of Rev DDX3X wt or K230A and TBK1 wt or K38M were
added as indicated. CAT expression was measured 24h post-trans-
fection by ELISA (Roche).
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(Figure 4C). Overall, these data support that DDX3X has a
positive role in the IFN pathway and is therefore required for
efﬁcient IFN production.
How does DDX3X affect IFN-b gene expression? Our data
are consistent with the possibility that DDX3X impinges on
IFN-b promoter activity directly. We therefore asked whether
DDX3X can be recruited to the IFN promoter. To address this
question, we used chromatin immunoprecipitation (ChIP)
and ampliﬁed the enhanceosome-binding region of the
IFN-b promoter by quantitative PCR (Figure 5A). IRF3, absent
under non-stimulated conditions, was recruited to the IFN
promoter upon infection with L. monocytogenes (Figure 5B).
The speciﬁcity of this signal was ascertained using a control
serum for ChIP. GS-TAP-tagged DDX3X, isolated by afﬁnity
puriﬁcation using rabbit IgG agarose, was also recruited to
the enhanceosome region upon L. monocytogenes infection
(Figure 5C). This recruitment was speciﬁc because a control
region (Figure 5A) could not be ampliﬁed by PCR under these
conditions. This suggests that DDX3X exerts a direct effect on
the IFN-b promoter.
To address whether DDX3X recruitment to the IFN-b
promoter depends on IRF3, we synthesized a biotinylated
double-stranded DNA fragment corresponding to the IFN-b
enhancer (Panne et al, 2007), along with two variants in
which the IRF3-binding site was either mutated or deleted
(Supplementary Figure 3A). We used these oligos as afﬁnity
reagents to monitor IRF3 or DDX3X engagement using lysates
from untransfected RAW264.7 cells. We found that the ap-
parent majority of IRF3 strongly associated with the wild
type, but only weakly with the mutated enhancer sequence
(Supplementary Figure 3B). On the other hand, a minor
fraction of DDX3X associated with both the wild-type and
the mutated enhancer sequence, suggesting that its binding is
independent of IRF3.
DDX3X as a TBK1 kinase substrate
Having established the importance of DDX3X in the TBK1-
dependent IRF3 pathway, we further investigated the mole-
cular nature of the relationship between TBK1 and DDX3X.
Given the weak afﬁnity of DDX3X for TBK1, we considered
the possibility of a kinase–substrate interaction. We observed
that coexpression of TBK1 with DDX3X is associated with a
slight shift in DDX3X migration on an SDS–PAGE
(Supplementary Figure 1). To investigate whether this shift
in migration was dependent on TBK1 kinase activity, we
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Figure 4 DDX3X and TBK1 led to synergistic activation of the IFN-b promoter. Cells were transfected with a ﬁreﬂy luciferase reporter plasmid
and a Renilla luciferase plasmid. Fireﬂy luciferase activity was measured after 24h and normalized to Renilla luciferase activity. (A) HEK293
cells were transfected with the IFN-b reporter plasmid and 1mg of plasmids encoding MAVS, DDX3X or DDX3X-K230A and 500ng of a TBK1
expression plasmid as indicated. (B) HEK293 cells were transfected with the NF-kB reporter plasmid and 1mg of plasmids encoding HA-tagged
MAVS, DDX3X or DDX3X-K230A and 500ng of a TBK1 expression plasmid as indicated. (C) MEFs from wt mice (black bars), TBK1-deﬁcient
mice (grey bars) or IRF3-deﬁcient mice (white bars) were transfected with the IFN-b reporter plasmid and 1mg of plasmids encoding HA-tagged
MAVS, DDX3X, TBK1 and TBK1-S172A as indicated.
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a putative phosphorylation site in the activation loop
(S172A), the ATP-binding site (K38M) or the catalytic base
(D135N). Activity of the TBK1 mutants was monitored by an
in vitro kinase assay or by immunoblotting using an antibody
that was raised against phosphoserine 172 in the activation
loop of TBK1. Whereas TBK1 wt was active in the kinase
assay (Supplementary Figure 4) and phosphorylated on
S172 (Figure 6A, middle panel), all mutants were inactive
and unphosphorylated on S172, suggesting that the antibody
is a valuable tool to monitor the activation status of TBK1
in vivo.
How does loss of TBK1 kinase activity affect DDX3X
migration? The aforementioned shift in migration was strictly
dependent on TBK1 kinase activity, as it was not seen when
different inactive mutants of TBK1 (TBK1 S172A, K38M or
D135N) were coexpressed with DDX3X (Figure 6A). To un-
equivocally prove that the shift in migration reﬂects a phos-
phorylation event, we added the non-selective kinase
inhibitor staurosporine and showed that the TBK1-induced
shift was strongly diminished in the presence of the drug.
Likewise, treatment of the cell extract with calf intestinal
phosphatase led to a decreased shift in DDX3X migration,
providing strong evidence that coexpression of TBK1 causes
DDX3X phosphorylation. In parallel, we compared DDX3X to
IRF3 in this assay (Figure 6A). Strikingly, the phosphoryla-
tion pattern observed for IRF3 mirrored the one obtained for
DDX3X. These results indicate that DDX3X and IRF3 are very
similar in terms of their TBK1 substrate quality.
To demonstrate whether the shift in DDX3X migration was
speciﬁc for TBK1, we coexpressed DDX3X with a number of
kinases including IKK-i, the closest relative of TBK1.
Interestingly, IKK-i could also phosphorylate DDX3X, but
DDX3X phosphorylation was not observed when the kinases
IKKa, IRAK1, Abl or FAK2 were coexpressed (Figure 6B). This
suggests that DDX3X is rather speciﬁcally phosphorylated by
TBK1 and IKK-i.
So far, the data presented supported the possibility that
DDX3X is a novel TBK1 substrate, although we could not
formally exclude the presence of an intermediate kinase
activated by TBK1. To rule out any indirect effect, we
expressed His-tagged IRF3, DDX3X and Grb2 in Escherichia
coli and puriﬁed them by HisTrap chromatography. Equal
amounts of puriﬁed proteins were then used for an in vitro
kinase assay using TBK1 puriﬁed from HEK293 cells.
Noteworthy, TBK1 alone (lane 1) or the substrates alone
(lanes 2, 6 and 10) did not produce any signal. IRF3 was
phosphorylated by TBK1 whereas Grb2 was not, suggesting
that the assay was performed under conditions that warrant
substrate speciﬁcity (Figure 6C). The signal obtained for
DDX3X was equivalent to the one obtained for IRF3, implying
that DDX3X is also a TBK1 substrate in vitro.
DDX3X phosphorylation site mapping
To map the phosphorylation site systematically, we decided
for a peptide array that displays 73 peptides containing all
serine and threonine residues of DDX3X (Supplementary
Figure 5). As a control, we included a peptide derived from
the TBK1 activation loop that contains putative auto-
phosphorylation site S172 (Figure 6A). As another control,
we included a peptide derived from the C-terminus of IRF3
that contains S396, one of the TBK1 target sites (Servant et al,
2003). As the control peptides contained several serines and
threonines, we sequentially exchanged these for alanines to
map which serine or threonine within these peptides was
actually phosphorylated. Incubation of the peptide array with
puriﬁed TBK1 produced a number of phosphorylation signals
(Figure 7A). The TBK1 control peptide was phosphorylated
by TBK1, suggesting that the activation loop is indeed an
autophosphorylation site. Mutagenesis indicates that the
phosphorylation occurs predominantly at S172, highlighting
the relevance of the antibody that recognizes phospho-S172
in TBK1 (Figure 6A). The peptide derived from IRF3 was
efﬁciently phosphorylated as well, but unexpectedly, the
phosphorylation occurred exclusively at S402. Analysing
the remaining hits in the peptide array, we identiﬁed 11
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Figure 5 DDX3X is recruited to the enhanceosome-binding site on
the IFN-b promoter. (A) Schematic representation of the IFN-b
promoter. Enhanceosome-binding site (white box) is ﬂanked by
speciﬁc primers, whereas a 1kb upstream region is ﬂanked by
control primers. (B) RAW264.7 macrophages were infected with
L. monocytogenes for 0–3h. Quantitative PCR was realized on ChIP
samples treated with either an IRF3-speciﬁc antiserum (black bar)
or an unrelated serum (white bar). (C) RAW264.7 NTAP(GS)-
DDX3X was infected with L. monocytogenes for 0–3h.
Quantitative PCR was realized on samples immunoprecipitated
with IgG beads with primers speciﬁc for either the enhanceo-
some-binding site (black bar) or the control region (white bar).
Sets of data were analysed using the paired Student’s t-test (two-
tailed, equal variance). Statistical signiﬁcance was assessed based
on the P-value: *Po0.05 and **Po0.01.
DDX3X helicase in interferon pathway
D Soulat et al
The EMBO Journal VOL 27 | NO 15 | 2008 &2008 European Molecular Biology Organization 2140potential phosphorylation sites in 9 DDX3X-derived peptides
(Figure 7A). Four of these target sites (S181, S183, S240 and
S269) were found in the DEAD domain that contains the
ATPase activity of DDX3X. The seven remaining sites were
scattered throughout the helicase domain (S429, T438, S442,
S456, S520, T542 and S543). We used the information
gathered in the peptide array to derive a TBK1 consensus
phosphorylation site (Figure 7B). Strikingly, TBK1 showed a
strong preference for serine over threonine. In fact, none of
the 12 peptides displayed on the array that contain exclu-
sively threonines was phosphorylated. Furthermore, we iden-
tiﬁed several preferences of TBK1 in terms of amino acids
adjacent to the actual site of phosphorylation, the most
striking being a preference for a hydrophobic amino acid (L
or F) in the þ1 position as also seen in the two control
peptides. It is interesting to note that S386, which has been
identiﬁed as critical for IRF3 activation (Mori et al, 2004),
also contains a Leu in the þ1 position.
To test which of those putative phosphorylation sites
are surface-exposed and therefore accessible to TBK1 in the
context of the folded protein, we mapped them onto the
structure of a truncated version of DDX3X that was recently
published (Hogbom et al, 2007). All sites except T542/S543
mapped to the surface of DDX3X (Figure 7C), implying that
the vast majority of these sites are bona ﬁde TBK1 phospho-
rylation sites in vivo.
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Figure 6 DDX3X is phosphorylated by TBK1. (A, B) HEK293 cells were transiently transfected with Myc- or HA-tagged constructs as indicated.
Cells were treated with 10mM staurosporine 1h before lysis as indicated. Cells were lysed 48h post transfection. Cell extracts were treated with
5U CIP for 1h as indicated. Cell extracts were analysed by immunoblotting using either anti-Myc (Rockland), anti-HA (Covance Research) or
an antiserum against phosphoserine 172 in TBK1. (C) GST-tagged IRF3, DDX3X and Grb2 were expressed in E. coli and puriﬁed by HisTrap
chromatography. Purity was assessed by Coomassie staining of three different dilutions of each protein (right panel). TBK1-mediated
phosphorylation was assessed by incubating the three potential substrates (IRF3, DDX3X and Grb2) with TBK1 in the presence of [g-
32P]ATP.
Lane 1 contains TBK1 without substrate, whereas lanes 2, 6 and 10 contain the substrates without TBK1 (left panel).
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with TBK1
To obtain phosphorylation-deﬁcient mutants for functional
experiments, we created three DDX3X mutants. We mutated
either all potential phosphorylation sites collectively (Pan-M)
or the phosphorylation sites in the DEAD domain (Dead-M)
or those in the helicase domain separately (Helic-M)
(Figure 8A). Mutagenesis did not include T542 or S543 as
those residues were predicted to disrupt the secondary struc-
ture of DDX3X. Again, we puriﬁed those DDX3X mutants
from E. coli and analysed TBK1-mediated phosphorylation
in vitro. DDX3X wt was strongly phosphorylated (Figure 8B).
In contrast, phosphorylation of Pan-M was strongly dimin-
ished as was the case for the Dead-M mutant. The Helic-M
mutant was also reduced in terms of TBK1 phosphorylation,
but the effect was less pronounced. On the basis of these
results, we conclude that both the DEAD domain and the
helicase domain contain at least one TBK1 phosphorylation
site and that the predominant phosphorylation event occurs
in the DEAD domain. We tested these DDX3X mutants for
their ability to synergize with TBK1 in the IFN-b reporter
assay. Although DDX3X wt showed a strong synergy with
TBK1, all the phosphosite mutants failed to enhance activity
of the IFN-b promoter (Figure 8C). This establishes a causal
link between TBK1-mediated phosphorylation of DDX3X and
the ability of the two proteins to stimulate IFN-b expression.
Discussion
As far as current knowledge goes, TBK1 is arguably the most
important kinase in the IFN pathway, yet we know of only
two substrates, IRF3 and IRF7 (Pichlmair and Reis, 2007). In
this study, we show that the DEAD-box helicase DDX3X is
required for IFN production. DDX3X is found to be a TBK1
substrate in vitro and in vivo and phosphorylation by TBK1 is
necessary for DDX3X to stimulate the IFN-b promoter. ChIP
suggests that DDX3X can be recruited to the IFN promoter,
positioning DDX3X downstream of TBK1 at the level of IRF3.
During these studies, we were also able to advance the
biochemical characterization of TBK1: ﬁrst, we identiﬁed and
characterized a set of inactive mutants (Figure 6). Second, we
developed a phospho-speciﬁc TBK1 antibody that can be
used to monitor TBK1 activity in vivo (Figure 6). Third, we
investigated the properties of TBK1 in vitro, using both
recombinant proteins and peptides as substrates. On the
basis of these analyses, we are providing what we believe
may be the ﬁrst consensus sequence for a TBK1 substrate,
which could be helpful for the future identiﬁcation of TBK1
target sites.
DEAD-box helicases constitute a large family of proteins
that comprises at least 38 members in humans (Linder, 2006).
These enzymes are characterized by the presence of nine
conserved motifs organized in two highly conserved do-
mains: a DEAD domain (named after the characteristic
amino-acid sequence D-E-A-D) and a helicase domain.
Their nucleic acid unwinding activity requires the hydrolysis
of ATP through Walker motifs present in the DEAD domain.
Although DEAD-box helicases are usually classiﬁed as RNA
helicases, it has been suggested that some of them, including
DDX3X, can also bind to DNA (Franca et al, 2007). Genetic
and biochemical experiments mainly realized in yeast sug-
gested that DEAD-box helicases could be involved at many
steps of RNA metabolism, including the initiation of the
transcription, RNA splicing, nuclear export, control of
mRNA translation and the regulation of RNA stability.
DDX3X is an X chromosome-encoded DEAD-box helicase
that has been implicated in nuclear export of HIV-1 RNA
through Rev/Crm1 (Yedavalli et al, 2004) and transcriptional
regulation of the p21waf1/cip1 promoter (Chao et al, 2006).
Both of these activities require access to the nuclear compart-
ment, which is achieved by the means of a nuclear localiza-
tion signal and a nuclear export signal. Incubation of cells
with nuclear export inhibitor leptomycin B traps DDX3X in
the nucleus (Yedavalli et al, 2004), conﬁrming that it is
shuttling between nucleus and cytoplasm.
DDX3X belongs to the same family of helicases as RIG-I
and MDA5 and yet, its mode of action in innate immunity
seems to be distinct: unlike RIG-I and MDA5, DDX3X does not
exert an effect as a PRR, but is situated rather downstream in
the signalling cascade that controls IFN-b production.
Furthermore, unlike RIG-I and MDA5, the DDX3X function
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implying that it may rather exert an effect as a scaffold than
as a helicase. A similar scenario has been described for other
transcriptional co-activators that exert an effect as bridging
factors to build the transcriptional activator complex
(Valineva et al, 2005).
Our data suggest that DDX3X is required for the function of
the TBK1/IRF3 module and that DDX3X exerts at least part of
this function at the promoter level. We would like to propose
that activated TBK1 phosphorylates DDX3X which, in the
nucleus, gets recruited to the IFN promoter where it stimu-
lates transcription of the IFN-b gene. How this effect is
brought about is currently unclear and will be the objective
of future studies. DDX3X has been reported to promote
transcription by direct interaction with transcription factors
(Chao et al, 2006). In our case, however, we fail to observe a
direct interaction between IRF3 and DDX3X and the associa-
tion of DDX3X with the IFN-b enhancer appeared to be
independent of the IRF3-binding site. This is reminiscent of
the direct association of DDX3X with the E-Cadherin promo-
ter (Botlagunta et al, 2008). On the basis of available litera-
ture, however, it is likely that the bulk of the DDX3X
molecular functions involve its RNA binding and helicase
function. So far, our attempts to ﬁnd evidence for a post-
transcriptional role of DDX3X in the IFN pathway have failed.
We cannot rule out the possibility that DDX3X may affect
IFN-b production at other stages of gene regulation as well.
For instances, DDX3X has been reported to bind to the cap-
binding protein complex (Shih et al, 2008). As capping is a
cotranscriptional event required for quality control of nascent
transcripts (Orphanides and Reinberg, 2002), one could spec-
ulate that DDX3X modulates transcriptional elongation of the
IFN-b gene. Additionally, there is the possibility of DDX3X
having an effect on nuclear export or translation of the IFN-b
mRNA. In fact, DDX3X has been implied in the nuclear export
of HIV-1 RNA (Yedavalli et al, 2004) on top of cap-dependent
mRNA translation (Shih et al, 2008), overall suggesting that
DDX3X may indeed interfere with IFN induction at different
stages (transcription, nuclear export and mRNA translation)
to allow for a ﬁne-tuning or fail saving of the process. This
may also explain why TBK1 seems to rely on at least two
substrates (IRF3 and DDX3X) to regulate IFN-b production.
The fact that DDX3X is necessary for IFN production
implies that it has an antiviral function. In apparent contra-
diction to this notion, hepatitis C virus (HCV) and HIV-1 seem
to exploit DDX3X and use it to their advantage (Yedavalli
et al, 2004; Ariumi et al, 2007): DDX3X is needed to sustain
the viral life cycle of HIV-1 by facilitating the nuclear export of
HIV-1 RNA (Yedavalli et al, 2004). Likewise, DDX3X binds to
the HCV core protein and supports viral replication (Ariumi
et al, 2007). This obvious contradiction, however, may be
resolved by interpreting it in light of the constant evolution-
ary struggle between host and pathogen: DDX3X may have
evolved as an antiviral protein, but viruses then, in turn,
developed strategies to hijack DDX3X function and use it for
their own beneﬁt, thereby counteracting the antiviral effect of
DDX3X. On the basis of this, we postulate that additional
viral DDX3X antagonists may exist that inactivate DDX3X
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Figure 8 Phosphorylation-deﬁcient DDX3X mutants fail to synergize with TBK1. (A) Phosphorylation sites obtained from the peptide array
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direct proteolytic cleavage or by altering its phosphorylation
pattern.
Materials and methods
Antibodies
The TBK1-speciﬁc antiserum was obtained from Cell Signaling. The
IRF3-speciﬁc antiserum was obtained from Invitrogen. The DDX3X-
speciﬁc antiserum was generated by immunizing rabbits using a
recombinant puriﬁed domain of DDX3X. Immunizations were
carried out by Eurogentec (Belgium).
Plasmids
All ESTs were obtained from RZPD (Berlin, Germany). Genes were
based on the following RefSeq IDs: Human DDX3X (NM_001356),
human IRF3 (NM_001571). HIV-1 Rev and the reporter plasmid
pDM128 were kind gifts of Dr Thomas Hope (University of
California, San Diego) and Dr Bryan Cullen (Duke University).
Mutagenesis of DDX3 was performed by custom gene synthesis
(Genscript Corporation, Piscataway, NJ, USA; www.genscript.com).
Tandem afﬁnity puriﬁcation
Tandem afﬁnity puriﬁcation using the GS-TAP cassette was
performed as described previously (Burckstummer et al, 2006).
Elution was performed by boiling the sample in SDS sample buffer.
siRNA treatment of RAW264.7 cells
siRNAs for TBK1 and DDX3X were purchased from Dharmacon.
RAW264.7 cells (2 10
4) were transfected with 25nM siRNA
complexed with HiPerFect (Qiagen) according to the manufacturer’s
instructions. Transfection was repeated once after 48h. At 72h after
the ﬁrst transfection, 5 10
5 cells were seeded onto 6cm dish to be
stimulated 24h later.
RAW264.7 stimulation
siRNA-treated RAW264.7 cells were infected with L. monocytogenes
LO28 at a multiplicity of infection of 10 for 4h. In parallel, cells
were transfected with 30mg/ml poly(I:C) (Amersham Biosciences)
complexed with HiPerFect (Qiagen) for 3h or 10mg/ml poly(dA:dT)
(Sigma) complexed with PolyFect (Qiagen) for 4h according to
manufacturer’s instructions. Additionally, cells were treated with
100ng/ml LPS derived from Salmonella minnesota (Alexsis) or with
500U/ml IFN-b (Calbiochem, La Jolla, CA) for 4h.
RNA isolation, cDNA synthesis and quantitative PCR
After stimulation, total RNA was extracted from RAW264.7 cells
using Nucleospin RNA II kit (Macherey & Nagel). The RNA was
then reverse transcribed with oligo(dT)18 primer and RevertAid
M-MuLV Reverse Transcriptase (MBI Frementas) according to the
manufacturer’s instructions. The cDNA was then analysed by
quantitative PCR using the iCycler IQ machine (Bio-Rad). The target
genes (IFN-b, RANTES, TNFa, IRF7 and Mx2) were quantiﬁed using
the standard curve method and normalized to the endogenous
control GAPDH. The PCR was performed by using SybrGreen
(Molecular Probes) and the Taq polymerase (MBI Fermentas) and the
following primers: GAPDH for, 50-CATGGCCTTCCGTGTTCCTA-30;
GAPDH rev, 50-GCGGCACGTCAGATCCA-30;I F N - b for, 50-TCAGAAT
GAGTGGTGGTTGC-30;I F N - b rev, 50-GACCTTTCAAATGCAGTAGA
TTCA-30;T N F a for, 50-CAAAATTCGAGTGACAAGCCTG-30;T N F a rev,
50-GAGATCCATGCCGTTGCC-30;I R F 7f o r ,5 0-CTGGAGCCATGGGTAT
GCA-30;I R F 7r e v ,5 0-AAGCAGAAGCCCAGACTGCT-30; Mx2 for, 50-CC
AGTTCCTCTCAGTCCCAAGATT-30; Mx2 rev, 50-TACTGGATGATCAAG
GGAACGTGG-30;R A N T E Sf o r ,5 0-CTCACCATCATCCTCACTGC-30;
RANTES rev, 50-ACTTGGCGGTTCCTTCG-30.
Rev reporter assay
HEK293 cells were seeded at 5 10
5 cells per well in six-well plates.
Cells were transfected with 500ng of pDM128 (Rev reporter
plasmid), 30ng of Rev expression plasmid, 300ng of DDX3X
expression plasmid and 500ng of TBK1 expression plasmid. All
samples were normalized for DNA content using an empty plasmid.
Cells were harvested 24h post-transfection and CAT levels were
analysed by ELISA (Roche) according to the manufacturer’s
instructions.
Generation of point mutant of TBK1 and DDX3X
QuikChange
s Multi Site-Directed Mutagenesis Kit (Stratagene) was
used to generate point mutants with appropriate primers regarding
the sequence to target.
Luciferase assay
HEK293 and MEF cells were transfected for 24h with the IFN-b
reporter (ﬁreﬂy luciferase) plasmid (pTA-Luc-IFN-b) or the NF-kB
ﬁreﬂy luciferase plasmid (pTA-Luc-NF-kB) together with the Renilla
luciferase control plasmid (phRG-TK) in complex with ExGen500
(MBI Fermentas) according to the manufacturer’s instructions. As
target vectors, N-HA-MAVS or N-HA-DDX3X plasmid (or derived
mutants) and/or myc-TBK1 (or derived mutants) plasmid were
used as indicated. Empty HA vector was used to equalize the DNA
content of each transfection. At 24h after the transfection, the cells
were lysed and the extracts were analysed by using the Dual-
Luciferase Reporter Assay System (Promega) and the luminometer
Lumat (LB9501; Berthold). For quantiﬁcation, the ﬁreﬂy luciferase
activity was then normalized to the Renilla luciferase activity.
ChIP
A total of 3 10
7 RAW264.7 wt or NTAP(GS)-DDX3X cells were used
per time point. ChIP assays were performed as recently described
(Zupkovitz et al, 2006) using 3mg of IRF3-speciﬁc antibody (Zymed,
Invitrogen) followed by a protein A pulldown or using rabbit IgG
agarose for NTAP(GS)-DDX3X. For the analysis of the enhanceo-
some-binding site of ifnb1 promoter, the following primers were
used: forward, 5-caggatgagcagctactctgc-3, and reverse, 5-ctgctacctg
caagatgagg-3. For the 1kb upstream control region, the following
primers were used: forward, 5-gccaatgatgtggttcagc-3, and reverse,
5-gagacctgtctgctgttagtgg-3.
Generation of the antiserum directed against phosphoserine
172 in TBK1
The phospho-speciﬁc antiserum was custom-synthesized by Euro-
gentec using a phosphorylated peptide derived from the activation
loop of TBK1 (DDEQFVpSLYGTEE) (Eurogentec).
Transient transfection of HEK293 and preparation of cell
extracts
HEK293 cells were transiently transfected using PolyFect (Qiagen)
according to the manufacturer’s instructions. Cells were harvested
24 or 48h post-transfection and lysed in Frackelton buffer (10mM
Tris–HCl pH 7.5, 50mM NaCl, 30mM sodium pyrophosphate, 1%
Triton X-100, 1mM DTT, 100mM sodium orthovanadate, 50mM NaF
and protease inhibitors).
Kinase assays
For peptide-based assays, Myc-TBK1 was isolated from HEK293
cells by immunoprecipitation using anti-Myc agarose (Sigma).
Precipitated TBK1 was incubated with a biotinylated peptide
derived from IRF3 (DLHISNSHPLSLC) in the presence of 50mM
ATP, 5 mCi [g-
32P]ATP and kinase buffer (40mM Tris–HCl pH 7.5,
10mM MgCl2 and 1mM DTT) for 30min at 301C. The reaction was
terminated by addition of guanidinium chloride (2.5M ﬁnal
concentration) and the reaction was spotted onto a SAM2 Biotin
Capture membrane (Promega) and further treated according to the
manufacturer’s instructions. Kinase activity was then measured by
scintillation counting.
For those kinase assays where recombinant proteins were used as
substrates, we puriﬁed those substrates from E. coli using HisTrap
chromatography (Amersham Biosciences). Recombinant TBK1 was
expressed in HEK293 cells and puriﬁed by afﬁnity chromatography
(data not shown). Puriﬁed TBK1 was incubated with three dilutions
of each puriﬁed substrate in the presence of 50mMA T Pa n d5 mCi
[g-
32P]ATP using kinase buffer (40mM Tris–HCl pH 7.5, 10mM
MgCl2 and 1mM DTT) at 301C. In some instances, the ATP
concentration was lowered to 10mM to increase substrate speciﬁcity.
The reaction was terminated by boiling in SDS sample buffer after
5–15min. Samples were separated by SDS–PAGE, the gels were dried
and analysed by autoradiography.
Peptide array
The peptide array was custom synthesized by Jerini Peptide
Technologies (Berlin, Germany). The peptide sequences that were
spotted on the array in triplicate are depicted in Supplementary
Figure 5. Recombinant TBK1 was expressed in HEK293 cells and
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array was incubated with TBK1 in the presence of 50mM ATP and
100 mCi [g-
32P]ATP using kinase buffer (40mM Tris–HCl pH 7.5,
10mM MgCl2 and 1mM DTT) at 301C. After 30min, the reaction
was terminated by addition of 0.1M phosphoric acid. The slides
were then washed with 0.1M phosphoric acid for ﬁve times and
with deionized water for ﬁve times. After a ﬁnal wash with
methanol, the slides were dried and analysed by autoradiography.
Structural mapping of phosphorylation sites and building
of the TBK1 phosphorylation consensus
The structure of DDX3 was downloaded from the Protein Database
(PDB) (accession number 2i4i). Phosphorylation sites were high-
lighted using PyMOL (www.pymol.org). The TBK1 phosphorylation
consensus was built by manual inspection of the TBK1 target
peptides taking into consideration only those amino acids that were
seen more than three times (out of 13 positive peptides). Amino-
acid sizes reﬂect the relative abundance of a given amino acid in
that particular position (e.g. Leu in position þ1 was found in 5 out
of 13 peptides and has therefore been represented as 5/13 of the
size of the S/T peak).
Statistical analysis
Sets of data were analysed using the paired Student’s t-test (two-
tailed, equal variance). Statistical signiﬁcance was assessed based
on the P-value: *Po0.05, **Po0.01 and ***Po0.001. For the
siRNA experiments (Figure 2), we calculated the standard deviation
and the statistical signiﬁcance (t-test) of the percentage of reduction
based on a minimum of three independent experiments. For
reporter gene assays (Figures 3, 4 and 8), we chose to show the
absolute level of induction (versus relative). The difference in
transfection efﬁciency across different experiments precludes the
calculation of standard deviations based on absolute levels. We
therefore decided to show one representative experiment and
hereby state that we have replicated each result at least twice, with
a statistically signiﬁcant difference in all three cases.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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